(+/-)-trans-4-(2,5-dimethylpiperazin-1-yl)-2-(trifluoromethyl)benzonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (+/-)-trans-4-(2,5-dimethylpiperazin-1-yl)-2-(trifluoromethyl)benzonitrile
• 英文别名: 4-(2alpha,5beta-Dimethyl-1-piperazinyl)-2-(trifluoromethyl)benzonitrile；4-[(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-(trifluoromethyl)benzonitrile
• 化学式: C₁₄H₁₆F₃N₃
• 分子量: 283.296
• InChiKey: XSUSILNKXHRYEW-VHSXEESVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  39.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (+/-)-trans-4-(2,5-dimethylpiperazin-1-yl)-2-(trifluoromethyl)benzonitrile 在 sodium perborate 、 溶剂黄146 作用下， 以 甲苯 为溶剂， 反应 76.17h， 生成 (+/-)-trans-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-piperazine-1-[N-(1-oxidopyridin-3-yl)]carboxamide
  参考文献：
  名称：

  (+)-(2R,5S)-4-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an Orally Potent and Peripherally Selective Nonsteroidal Androgen Receptor Antagonist

  摘要：

  A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED50 = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.

  DOI：

  10.1021/jm050293c
• 作为产物：
  描述：

  4-氟-2-(三氟甲基)苯甲腈 在 di-benzoyltartaric acid 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 (+/-)-trans-4-(2,5-dimethylpiperazin-1-yl)-2-(trifluoromethyl)benzonitrile
  参考文献：
  名称：

  (+)-(2R,5S)-4-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an Orally Potent and Peripherally Selective Nonsteroidal Androgen Receptor Antagonist

  摘要：

  A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED50 = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.

  DOI：

  10.1021/jm050293c

文献信息

• Cyanophenyl derivative
  申请人：Yamanouchi Pharmaceutical Co. Ltd.

  公开号：US06673799B1

  公开（公告）日：2004-01-06

  This application relates to a piperazino-substituted novel cyanophenyl derivative in which a substituted carbamoyl or substituted sulfamoyl group having an aryl, heterocyclic or the like group that may have a substituent group is bonded to one nitrogen atom on the piperazine ring. The compound of this application has an anti-androgen action and is useful in preventing or treating prostatic cancer, benign prostatic hyperplasia and the like diseases.

  该申请涉及一种哌嗪取代的新型氰基苯基衍生物，其中带有芳基、杂环或类似的基团的取代羰酰基或取代磺酰基与哌嗪环上的一个氮原子结合。该申请的化合物具有抗雄激素作用，并可用于预防或治疗前列腺癌、良性前列腺增生等疾病。
• N-Arylpiperazine-1-carboxamide Derivatives: a Novel Series of Orally Active Nonsteroidal Androgen Receptor Antagonists
  作者：Isao Kinoyama、Nobuaki Taniguchi、Eiji Kawaminami、Eisuke Nozawa、Hiroshi Koutoku、Takashi Furutani、Masafumi Kudoh、Minoru Okada

  DOI：10.1248/cpb.53.402

  日期：——

  A novel series of N-arylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic properties were evaluated. Reporter assays indicated that trans-2,5-dimethylpiperazine derivatives are potent AR antagonists, and in this series trans-N-4-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,4-difluorophenyl)-2,5-dimethylpiperazine-1-carboxamide (18g, YM-175735) exhibited the most potent antiandrogenic activity. Compared to bicalutamide, YM-175735 is an approximately 4-fold stronger AR antagonist and has slightly increased antiandrogenic activity, suggesting that YM-175735 may be useful in the treatment of prostate cancer.

  合成了一系列新型N-芳基哌嗪-1-羧酰胺衍生物，并评估了它们的雄激素受体（AR）拮抗活性和体内抗雄激素特性。报告实验表明，反式-2,5-二甲基哌嗪衍生物是有效的AR拮抗剂，在这一系列化合物中，反-N-4-[4-氰基-3-(三氟甲基)苯基]-N-(2,4-二氟苯基)-2,5-二甲基哌嗪-1-羧酰胺（18g，YM-175735）表现出最强的抗雄激素活性。与比卡鲁胺相比，YM-175735的AR拮抗活性约强4倍，且抗雄激素活性略微增强，这表明YM-175735可能在前列腺癌治疗中具有潜在的应用价值。
• CYANOPHENYL DERIVATIVES
  申请人：Astellas Pharma Inc.

  公开号：EP1122242B1

  公开（公告）日：2008-01-16
• US6673799B1
  申请人：——

  公开号：US6673799B1

  公开（公告）日：2004-01-06